Literature DB >> 3021800

The selection and characterization of human monoclonal antibodies to human cytomegalovirus.

M J Redmond, M Leyritz-Wills, L Winger, D G Scraba.   

Abstract

This communication describes the application of Epstein-Barr virus lymphocyte transformation technology to the production of human monoclonal antibodies specific for human cytomegalovirus. A group of such IgG antibodies have been characterized in terms of subclass, light-chain composition, specificity for particular viral proteins and neutralizing capacity. These results have shown that the production of antibodies by transformed lymphocytes is representative of the in vivo human immune response; the antibodies produced may therefore be of therapeutic value. This approach should prove to be useful for the identification of specific virion proteins which are antigenic in humans and for the in vitro evaluation of the immune responses to synthetic peptide vaccines.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021800     DOI: 10.1016/0166-0934(86)90003-0

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  3 in total

1.  Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus.

Authors:  M Ohlin; V A Sundqvist; G Gilljam; U Rudén; F O Gombert; B Wahren; C A Borrebaeck
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

2.  Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning.

Authors:  Thomas Tiller; Eric Meffre; Sergey Yurasov; Makoto Tsuiji; Michel C Nussenzweig; Hedda Wardemann
Journal:  J Immunol Methods       Date:  2007-10-31       Impact factor: 2.303

Review 3.  Exploring the native human antibody repertoire to create antiviral therapeutics.

Authors:  S K Dessain; S P Adekar; J D Berry
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.